Biotech Stocks Facing FDA Decision In January 2025

The FDA decision on Datopotamab Deruxtecan, proposed for the treatment of patients with previously treated metastatic HR-positive, HER2-negative breast cancer, is due on January 29, 2025.

from RTT - Top Story https://ift.tt/amX5u0x
via IFTTT